The intelligence of machines and the branch of computer science which aims to create it

Artificial Intelligence Journal

Subscribe to Artificial Intelligence Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Artificial Intelligence Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

Artificial Intelligence Authors: Elizabeth White, Liz McMillan, Corey Roth, Yeshim Deniz, Pat Romanski

Related Topics: CEOs in Technology, Artificial Intelligence Journal, Datacenter Automation, Farming & Forestry, Biotech News Journal, Government News, Construction News, CFOs in Technology

News Feed Item

Ceapro Reports Full-Year 2013 Financial and Operating Results

- Highest full year revenue in Ceapro's history: Total sales increased by 26.3% or $1,359,000 over the year ended December 31, 2012

EDMONTON, ALBERTA -- (Marketwired) -- 04/28/14 -- Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") today announced its financial results and operational highlights for the year ended December 31, 2013.

"Year 2013 will be remembered as the most solid year ever in the history of Ceapro. Not only did we achieve a net profit and the best sales results with a 26.3% increase over 2012, but we did it during a year of major investments for the acquisition of equipment and the construction of a new facility. Our dedicated employees deployed tremendous efforts to respond to the growing demand while working diligently to plan and implement our new state of the art bioprocessing facility" said Gilles Gagnon, President and CEO. "Also, this major achievement would have not been possible without the unconditional support and vote of confidence from our major long term partners, Symrise AG, Alberta Financial Services Corporation and AI Bio Solutions" he added.


--  Total sales of $6,524,000 compared to $5,165,000 in 2012, an increase of
    26.3%. This sales increase is mostly attributed to a 28% increase for
    flagship product, avenanthramides
--  Net Profit of $176,000 compared to a net loss of $538,000 in 2012
--  Research and Development investments of $731,000 compared to $856,000 in
--  General and Administration expenses of $1,709,000 compared to $1,795,000
    in 2012
--  Sales and Marketing expenses of $85,000 compared to $199,000 in 2012
--  The Company has Cash and cash equivalents of $1,953,000 as of December
    31, 2013 as compared to $273,000 as of December 31, 2012


--  Signing of a long term license and distribution agreement with German-
    based multinational, Symrise AG, a leading provider of active
    ingredients for personal care
--  Signing of two loan agreements at attractive interest rates, which is
    demonstration of confidence in Ceapro
--  Completed non-dilutive financing for the acquisition of customized
    equipment and construction of the state-of-the-art facility in Edmonton,
--  Signed an Agri-Processing Automation and Efficiency Grant Agreement with
    Alberta Agriculture and Rural Development for a contribution up to
--  Successful development of dry formulations for beta glucan and
--  Obtained key patents for beta glucan in Europe and Japan and for
    avenanthramides in the USA

"2013 has been marked by significant strategic achievements as we continued to move our products through pipeline and materially strengthened our cash position. With these conditions combined with our current strong order book and upcoming strategic initiatives, we are well positioned to pursue our focused pipeline development strategy with dry formulations. This is an exciting time for all of us at Ceapro, as well as for our partners and shareholders " added Mr. Gagnon.

The complete financial statements are available for review on SEDAR at and on the Company's website at

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Consolidated Statements of Net Income (Loss) and Comprehensive Income

                                                     Year Ended December 31
                                                     2013              2012
                                                        $                 $

Revenue (note 13)                               6,524,062         5,165,276
Cost of goods sold                              3,425,248         2,716,605

Gross margin                                    3,098,814         2,448,671

Research and product development                  731,174           856,191
General and administration                      1,709,053         1,795,476
Sales and marketing                                84,897           198,650
Finance costs (note 16)                           126,663           112,900

Income (loss) from operations                     447,027          (514,546)

Other operating loss (note 15)                   (271,219)          (23,807)

Net income (loss) for the year                    175,808          (538,353)

Other comprehensive loss
Actuarial loss on employee future
 benefit obligation (note 10)                     (16,916)                -

Total comprehensive income (loss) for
 the year                                         158,892          (538,353)

Net income (loss) per common share (note
  Basic                                              0.00             (0.01)
  Diluted                                            0.00             (0.01)

Weighted average number of common shares
 outstanding                                   60,278,948        60,278,948

Branko Jankovic
Vice President and CFO
Ceapro Inc.
T (Edmonton): 780.917.8376
E: [email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.